Facial Wasting (Lipoatrophy) & HIV/AIDS: Research
- Cosmetic Treatment for Facial Fat Loss Safe and Effective in the Long Term (April 27, 2009)
From aidsmap.com
- Leptin Injections May Help HIVers With Lipoatrophy, Other Metabolic Problems, According to Small Study (April 2009)
The full text of a study published in the Journal of Clinical Endocrinology & Metabolism.
From National AIDS Treatment Advocacy Project
- Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? (April 2009)
Christos Mantzoros, M.D., an associate professor at Harvard Medical School, offers his take on whether there's a future for leptin replacement as a treatment for metabolic complications in people with HIV. (Editorial originally published in the Journal of Clinical Endocrinology & Metabolism.)
From National AIDS Treatment Advocacy Project
- Can Low-Dose Ritonavir Help Preserve Body Shape? (April 1, 2009)
In CATIE News, from Canadian AIDS Treatment Information Exchange
- Rosiglitazone for Lipoatrophy (Winter/Spring 2009)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Sculptra Continues to Increase Facial Volume More Than Six Months After Injections, Study Finds (January 4, 2009)
An abstract of a published study.
In HIV Medicine
- Objective Amount of Limb Fat in HIV-Infected Subjects With Subjective Diagnosis of Lipoatrophy (September 25, 2008)
In HIV Medicine, from British HIV Association
- U.S. Study Confirms Long-Term Use of AZT, d4T Result in Lipoatrophy (May 27, 2008)
From aidsmap.com
- A Facial Filler May Cause Problems Long After It's Taken, Study Finds (May 20, 2008)
In Medscape
- Taking a Half Dose of d4T Doesn't Reduce Fat Loss (April 16, 2008)
From aidsmap.com
- Genetics May Protect Some From Lipoatrophy (March 18, 2008)
From aidsmap.com
- Study Looks at How Much Fat a Person Can Lose Without Noticing It (February 11, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy (December 15, 2007)
In Journal of Acquired Immune Deficiency Syndromes
- ICAAC: Gains in Limb Fat and CD4 Counts Continue Three Years After Switching From d4T to Tenofovir (September 21, 2007)
From aidsmap.com
- Switching to NRTIs Less Associated With Lipoatrophy Is Successful (July 25, 2007)
Since thymidine-sparing, NRTI-based regimens are associated with fewer instances of lipoatrophy and hyperlipidemia than thymidine-containing, NRTI-based regimens, switching to a thymidine-sparing, fixed-dose combination of NRTIs is feasible and associated with no unexpected adverse events, including those affecting renal function and bone mineral density. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
- Canadian Study Finds Bio-Alcamid Safe, Effective for Facial Lipoatrophy (May 22, 2007)
From aidsmap.com
- Glitazones Do Not Reverse Lipoatrophy (May 8, 2007)
From AIDSMeds.com
- FDA Approves Radiesse for Treating Facial Lipoatrophy (December 29, 2006)
From U.S. Food and Drug Administration
- Comparing the Effects of Rosiglitazone, Pravastatin, Recombinant Human Growth Hormone and Combinations Thereof on HIV-Associated Lipodystrophy (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Long-Term Safety and Efficacy of Poly-L-Lactic Acid in the Treatment of HIV-Related Facial Lipoatrophy (April 7, 2006)
In HIV Medicine, from British HIV Association
- Treatment of Facial Lipoatrophy With Intradermal Injections of Polylactic Acid in HIV-Infected Patients (April 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
|
|
Advertisement
|
E-Mail
Glossary
Share
